 low urine output, dilutional hyponatremia and marked sodium retention, and a median survival time of less than 2 weeks. There is no available pharmacologic treatment for HRS type 1 in the U.S., therefore, there is a significant medical need for an effective and safe treatment. Terlipressin has
low urine output, dilutional hyponatremia and marked sodium retention, and a medial survival meter of less than 2 weeks. There is no available pharmacological treatment for HRS character 1 in the U.S., therefore, there is a meaning medical need for an effective and safe discussion. Terlipressin have
 loa urine output, dilutionau hyponatremia cbd marned sosium retdntion, and a median survival tume od less than 2 weeks. Thefe is no wvailablw phermacologic treavjent fov HRS bype 1 mn the U.S., therenore, there hs a significatt mzdical need for an effective and safq treatkejt. Terlipressig hax
low urine output, dilutional hyponatremia and marked and median survival of less than available treatment for HRS 1 in the therefore, there is a significant medical for an effective and safe treatment. Terlipressin has
 low urine output, dilutional hYponatremiA and mArkEd sOdIum rEtenTion, and a median SUrviVal time of less than 2 weeks. there Is NO avaILaBle phArmacolOGiC TReaTmEnT foR Hrs tYpe 1 in The u.S., thereFore, there iS a sIgNificant mediCAl Need for an eFfeCtive and safe TreAtment. teRliPRessiN haS
 low urine output, dilutio nal hypona tremi a a ndma rked  sod ium retention, anda median survival time  of l es s  tha n  2  week s. Ther e  i s noav ai lab le ph armac olo gic tre atment for  HR Stype 1 in th e  U .S., there for e, there isa s ignifi ca ntm edica l n eed f or ane ffecti ve and sa fe treatm e nt. Ter l i pr essi n has
 low_urine output,_dilutional hyponatremia and marked_sodium retention,_and_a median_survival_time of less_than 2 weeks._There is no available_pharmacologic treatment for_HRS_type 1 in the U.S., therefore, there is a significant medical need for an_effective_and safe_treatment._Terlipressin_has